Epidemiology, Health Policy, and Outcomes

28T45: 2025 Rheumatology Update from the FDA

Moderator(s)

• RN

  Raj Nair, MD, RhMSUS

  Food and Drug Administration
  Rockville, Maryland, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose
• MW

  Michael Weisman, MD

  Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA
  LOS ANGELES, California, United States

  Disclosure(s): Spyre Therapeutics: Consultant (Ongoing), Independent Contractor (Ongoing)

Session Coordinator(s)

• 

  Gregory Gardner, MD

  University of Washington
  Anacortes, Washington, United States

  Disclosure information not submitted.

This session includes faculty participating virtually who will join live and engage with the audience in real time.

New therapies in rheumatology as well as new indications for existing medications are constantly being reviewed and approved by the FDA. The purpose of this session is to update rheumatologists on changes to our therapeutics including CAR-T and multi-specific therapies. Discussion of newly approved agents and indications as well as safety issues will take place as well as reviewing FDA issues with newer immune therapies.

Presentations:

• 1:00 PM - 1:20 PM Central Time

  Update on New Therapies in Rheumatology
• 1:20 PM - 1:40 PM Central Time

  Safety Issues for Therapies in Rheumatology
• 1:40 PM - 1:55 PM Central Time

  The FDA and CAT- T Therapies
  

  Speaker: Anam Tariq
• 1:55 PM - 2:10 PM Central Time

  The FDA and Multi-Specific Immune Therapies
• 2:10 PM - 2:30 PM Central Time

  FDA Update Panel Discussion